Apixaban for treating calf vein blood clots
Treatments studied
Part of Heart & circulation clinical trials.
This study compares a drug called apixaban (a blood thinner) with usual care to treat blood clots in the calf veins. The goal is to see if apixaban reduces the risk of the clot worsening or moving to a more dangerous location.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a blood clot in a deep calf vein that was found by ultrasound and that has been causing symptoms for less than 10 days.
- You must not be on blood thinners (beyond a preventive dose) when the clot is found, unless you had a blood thinner directly related to the clot for less than 48 hours.
- You must not have a blood clot that has moved to a larger vein above the knee or to your lungs.
- You must not have active cancer or be receiving cancer treatment, and you must have finished any cancer treatment more than 6 months ago.
- You must not have severe kidney or liver problems, low platelet count, ongoing bleeding, or high risk of bleeding.
- You must not be pregnant or breastfeeding, and your weight must be between 40 kg and 120 kg.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if the blood thinner apixaban is safe and effective for cancer patients who have low platelets and a recent blood clot. It may offer a treatment option for those who cannot take standard blood thinners.
This trial studies a procedure to remove an acute deep vein blood clot in the leg. It may help restore blood flow faster than standard treatment for certain clot locations.
This trial tests whether a medication called apixaban (a blood thinner) can safely prevent blood clots after abdominal or pelvic surgery. It is for people who have a moderate risk of clots and bleeding, and who are not taking other blood thinners.
This trial tests whether the blood thinner apixaban can prevent dangerous blood clots from forming in the heart's main pumping chamber after a specific type of heart attack. It is for patients who have severe weakness of the left ventricle and no clot already present.
This trial tests different ways to take the blood thinner apixaban to prevent blood clots in people with cancer who are starting or switching their cancer treatment. It aims to find the best dose for safety and effectiveness.
This trial tests apixaban (a blood thinner) to prevent stroke in people with atrial fibrillation or atrial flutter who have very poor kidney function or are on dialysis. If you qualify, you may help researchers find a safer way to lower stroke risk for this higher-risk group.
Hear when a new Deep Vein Thrombosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.